BlackRock Group’s Impax Laboratories, Inc. IPXL Stock Holding History

BlackRock Group’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.03M	Buy	153,173 +49,899	+48%	+$853K	﹤0.01%	1759
2016 Q3	$2.45M	Buy	103,274 +5,881	+6%	+$158K	﹤0.01%	1479
2016 Q2	$2.81M	Buy	97,393 +6,416	+7%	+$209K	﹤0.01%	1357
2016 Q1	$2.91M	Buy	90,977 +11,347	+14%	+$399K	﹤0.01%	1311
2015 Q4	$3.4M	Buy	79,630 +857	+1%	+$34.2K	﹤0.01%	1230
2015 Q3	$2.77M	Buy	78,773 +1,886	+2%	+$85K	﹤0.01%	1326
2015 Q2	$3.53M	Buy	76,887 +13,145	+21%	+$624K	﹤0.01%	1269
2015 Q1	$2.99M	Buy	63,742 +2,350	+4%	+$93.5K	﹤0.01%	1310
2014 Q4	$1.95M	Buy	61,392 +3,276	+6%	+$95.9K	﹤0.01%	1488
2014 Q3	$1.38M	Sell	58,116 -1,969	-3%	-$50.4K	﹤0.01%	1597
2014 Q2	$1.8M	Sell	60,085 -34,835	-37%	-$940K	﹤0.01%	1515
2014 Q1	$2.51M	Sell	94,920 -2,089	-2%	-$52.2K	﹤0.01%	1426
2013 Q4	$2.44M	Buy	97,009 +8,185	+9%	+$183K	﹤0.01%	1399
2013 Q3	$1.82M	Buy	88,824 +13,649	+18%	+$282K	﹤0.01%	1522
2013 Q2	$1.5M	Buy	+75,175	New	+$1.33M	﹤0.01%	1462

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Group's IPXL Position: Q4 2016 in Review

BlackRock Group increased its Impax Laboratories, Inc. (IPXL) stake by 48% in Q4 2016, buying an estimated $853K and bringing the position to 153,173 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

BlackRock Group first reported a position in IPXL in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.53M in Q2 2015. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

BlackRock Group held 153,173 shares of Impax Laboratories, Inc. worth $2.03M as of Q4 2016.
BlackRock Group bought 49,899 Impax Laboratories, Inc. shares in Q4 2016, an estimated $853K.
Impax Laboratories, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1759 holding.
BlackRock Group first reported a position in Impax Laboratories, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Group's Impax Laboratories, Inc. position peaked at $3.53M in Q2 2015.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.